Joseph Tucker, PhD, CEO of Enveric Biosciences, Naples, FL, discusses using cannabinoids, specifically cannabidiol in a topical administration, to tackle the widespread problem of radiation dermatitis in cancer patients. Dr Tucker highlights the importance of strict clinical trials to test the efficacy and safety of cannabinoids, in order for physicians and patients to be comfortable using these treatments.
This video presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors. A discussion of these factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.